Lydus Medical, a portfolio company of Sanara Ventures – a joint venture by Teva and Philips and an anastomosis technology provider – announced on Monday $2.7 million in a Pre-A funding, led by a leading US based strategic player with the participation of Sanara Ventures and existing shareholders.
Follow Israel Hayom on Facebook and Twitter
Lydus takes an innovative approach to surgical anastomosis, the connection of ultra-small blood and lymph vessels to one another and has developed the Vesseal, a device that enables precise, symmetrical and rapid connection of blood and lymph vessels of tiny diameters, ranging from 4.0 to 0.5mm, to be used in procedures ranging from breast reconstruction and lymphedema to bypass surgery and vascular access for hemodialysis.
"Anastomosis is one of the most complicated steps of surgery, and the key to success of many procedures, and it is still performed manually, making it time and labor intense, requiring high surgeon dexterity and a very unique skill set very few surgeons worldwide possess. This reality often results in poor clinical outcomes," said CEO Jessica Weiss.
"Lydus technology delivers standardized, accurate anastomosis, significantly improving clinical results, shortening operation time and enabling successful microsurgery procedures even when a rare, highly skilled microsurgeon isn't available."
